New drug combo shows promise for Tough-to-Treat breast cancer
NCT ID NCT07543250
First seen Apr 23, 2026 · Last updated May 19, 2026 · Updated 6 times
Summary
This study looks at how well a drug called inavolisib works in everyday medical practice for people with a specific type of advanced breast cancer (HR-positive, HER2-negative, with a PIK3CA mutation). About 100 participants will receive inavolisib combined with hormone therapy, with or without another drug. The main goal is to see how long it takes for the cancer to progress or for death to occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.